Edition:
India

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

2.95USD
9:49pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.95
Open
$3.00
Day's High
$3.00
Day's Low
$2.83
Volume
13,131
Avg. Vol
44,449
52-wk High
$6.45
52-wk Low
$2.75

Select another date:

Tue, Jan 9 2018

BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial

* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL

BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics

* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage:

BRIEF-Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine

* AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE

BRIEF-Axsome Therapeutics reports Q3 loss per share $0.27

* Axsome Therapeutics reports third quarter 2017 financial results

BRIEF-Axsome enters agreement to sell up to $30 mln of shares of co's common stock

* Axsome Therapeutics-entered sales agreement to sell through leerink up to $30 million of shares of co's common stock,par value $0.0001/share-SEC filing Source text : (http://bit.ly/2gxqvzm) Further company coverage:

BRIEF-Axsome Therapeutics reports Q2 loss per share $0.30

* Axsome Therapeutics reports second quarter 2017 financial results

BRIEF-Axsome Therapeutics announces AXS-06 meets primary endpoint in phase 1 clinical trial

* Axsome Therapeutics announces AXS-06 (moseic meloxicam and esomeprazole) meets primary endpoint in phase 1 clinical trial

Select another date: